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Giant prolactinomas are rare pituitary tumours of which
management can be a challenge. A 28-year-old man
presented with headaches, visual impairment and
behavioural changes. Clinically, the patient was found to
have hypogonadism and bitemporal hemianopsia. A MRI
demonstrated a pituitary tumour 76 mm in diameter and
blood tests revealed a serum prolactin of 158 700 mU/mL
(reference range 58–254). Initially, a craniotomy was
performed. Immunohistochemistry of the tumour
identified a prolactinoma with a high proliferative index
and the patient was started on treatment with a
dopamine agonist. A year later, neurological symptoms
worsened due to regrowth of the lesion’s cystic
component, and so further surgery was performed. After
10 years of treatment with dopamine agonists, the
prolactin levels decreased by 96.8%, there was an
effective reduction in tumour size, and the neurological
signs and symptoms resolved.
BACKGROUND
A giant prolactinoma is a pituitary tumour with a
diameter of 40 mm or more, significant extrasellar
extension, very high prolactin concentrations
(usually above 1000 ng/mL) and no concomitant
growth hormone (GH) or adrenocorticotrophin
(ACTH) secretion.1
Although prolactinomas are the most common
functioning pituitary adenomas, giant prolactino-
mas are very rare, accounting for 2–3% of prolacti-
nomas and only 0.5% of all pituitary tumours.1 2
These tumours have a significant male preponder-
ance with a median age at diagnosis of 42 years
(24–59).3
Giant prolactinomas often present with neuro-
logical rather than endocrine symptoms.4 These
occur due to compression of the surrounding struc-
tures by large or invasive tumours and include
headache, visual field defects and diplopia. Some
patients may have clinical features of hypogonad-
ism, such as decreased libido and impotence and
infertility.5
The classical therapeutic goals of prolactinomas,
namely correction of hyperprolactinaemia and
hypogonadism, and tumour size reduction, are
usually not realistic in giant prolactinomas, there-
fore the first goal of treatment is to improve the
neurological symptoms.1 These entities are usually
managed via medical therapy with dopamine ago-
nists (DAs), however, surgery followed by radio-
therapy may be warranted in some cases.1 6
Nevertheless, giant prolactinomas have invasive
characteristics, and so treatment is rarely curative.
Patients typically need lifelong medical treatment to
manage their symptoms.1 It is clear that the
therapeutic management of these tumours is a chal-
lenge and there are few reports of long-term
follow-up.5 7 Long-term follow-up of giant prolac-
tinomas may contribute to a better understanding
of the course of disease and thereby improve
patients’ management. We report a case of a giant
prolactinoma in a young man who presented with
headaches, vision impairment and behavioural
changes, and discuss the long-term management
challenges of these tumours.
CASE PRESENTATION
A 28-year-old man presented at the emergency
room (ER), referred by an ophthalmologist, with a
2-year history of frontal headaches and visual dis-
turbances, and a 1 year history of behavioural
changes, namely disinhibition. Additionally, in the
previous 3 months, he had polyphagia and weight
gain of 10 kg.
The patient had no history of head trauma and
denied other neurological symptoms. The systems
review was otherwise unremarkable. He had no
past medical history, drug history or family history
to help account for his condition.
On examination, he had poorly defined second-
ary sexual characteristics and was obese. There
were no other stigmata of endocrine dysfunction.
Peripheral nervous system examination was normal,
and cranial nerve examination was normal except
for a bi-temporal visual field defect. Funduscopy
was also normal.
INVESTIGATIONS
The referring ophthalmologist arranged visual field
campimetry, which revealed a bitemporal hemian-
opsia, and so a cerebral MRI was performed.
Cerebral MRI revealed a large invasive pituitary
mass, 76 mm in diameter. It had suprasellar exten-
sion, a large anterosuperior cystic component and a
posteroinferior solid component, with close prox-
imity to vascular and neural structures of the skull
base (figure 1A, B).
Laboratory evaluation revealed a very high prolac-
tin level of 158 700 mU/mL (reference range
58–254); low testosterone value (229 ng/dL, refer-
ence range 270–1734), luteinising hormone of
1.15 μIU/mL (reference range 1–9) and follicle
stimulating hormone of 2.35 μIU/mL (reference
range 0.7–11.1). Thyroid function tests were
normal: free thyroxine (FT4) 1.02 ng/dL (reference
range 0.8–1.9) and thyrotropin (TSH) 3.69 μIU/mL
(reference range 0.4–4.0). The patient’s GH value
was 0.08 ng/mL (reference range <1.00). The
ACTH and cortisol levels (obtained at 12 o’clock
in the ER) were 8.9 pg/mL and 6.74 μg/dL,
respectively.
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TREATMENT
In view of his clinical symptoms and imaging, a craniopharyn-
gioma was suspected, and the patient underwent a craniotomy.
Surgery occurred under corticosteroid therapy and there were
no complications. Immunohistochemistry revealed a densely
granulated adenoma, with strong diffuse immunostaining for
prolactin, a high proliferative index (Ki-67: 7%) and p53 immu-
noreactivity of 42%. The diagnosis of a giant prolactinoma was
established. Six months later, the tumour measured 60×48 mm
(figure 2A). One year after the surgery, there was regrowth of
the tumour’s cystic component to 65×42 mm and the patient’s
behavioural changes returned (figure 2B). Therefore a redo cra-
niotomy was performed. There were no hormonal deficits after
the surgeries.
The patient was started on bromocriptine after the first
surgery and this drug was titrated up to 45 mg/day. However,
biochemical response to the bromocriptine was poor and this
DA was changed to cabergoline. Again his dose was titrated up
to 5 mg/week.
OUTCOME AND FOLLOW-UP
After the second surgery there was significant clinical improve-
ment, with complete resolution of the neurological and visual
symptoms. However, 2 years after the initial diagnosis, the
patient developed seizures and was therefore started on anticon-
vulsants. Although hypogonadism resolved 6 months after the
initial surgery (testosterone 431 ng/dL, normal range 270–1734)
it returned 2.5 years later and testosterone therapy was initiated
(testosterone enanthate 250 mg, intramuscular, every 4 weeks).
Secondary hypothyroidism developed 4 years after presentation
and the patient was started on levothyroxine 75 μg/day.
At 5 years of follow-up, prolactin levels had decreased by
94.7% (figure 3) and pituitary MRI showed persistence of a
tumour capsule adherent to the visual pathways, skull base and
its vessels, extending to the third ventricle (figure 4A, B).
After 10 years of follow-up, the patient is continued on caber-
goline 5 mg/week, with no associated cardiac complications.
Prolactin levels have decreased by 96.8% and the lesion remains
stable (figure 3). His most unstable and frequent clinical features
are convulsions in the form of absence seizures and simple
partial seizures (average 2–3 episodes per year), despite treatment
with several different antiepileptic drugs. This complication has
led to partial loss of autonomy and decreased quality of life.
DISCUSSION
As described in almost all reports of giant prolactinomas, our
patient is a young man. It has been described that
Figure 1 (A) MRI at diagnosis (coronal view). (B) MRI at diagnosis
(sagittal view).
Figure 2 (A) MRI at 6 months of follow-up. (B) MRI at 12 months of
follow-up.
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microprolactinomas are more prevalent in women and macro-
prolactinomas more common in men.8 This is probably due to
an earlier diagnosis in women, due to easier recognition of the
endocrine consequences of hyperprolactinaemia, namely galac-
torrhoea, menstrual disturbances and infertility.8 9 Some authors
also argue that prolactinomas tend to be more aggressive in
males, and that this fact could explain the highest prevalence of
giant prolactinomas in this gender.10
In our case, the patient presented with neurological symptoms
(headache and visual disturbance) that resulted from compres-
sion of pituitary surrounding structures by a very large and inva-
sive tumour of 76 mm of diameter, and his behavioural changes
could be explained by the antero-superior growth of the tumour
to the frontal lobe.3
Currently, DAs are the first-line treatment for all prolactino-
mas, including giant prolactinomas.1 8 There are several reports
of a pronounced and fast response of these tumours to this
medical therapy.4 7 11 Nevertheless, the majority of patients
with giant prolactinomas need lifelong medical therapy and cure
is very rare.1
When our patient was observed for the first time in the ER,
none of the doctors from the pituitary group were present. A
presumptive diagnosis of craniopharyngioma was performed
and clinical presentation, with behavioural changes and visual
impairment, led to a rapid surgical intervention. However, it is
worth emphasising the need to determine serum prolactin in all
invasive skull base tumours and to consider DA therapy as
primary treatment when the prolactin level is above 1000 ng/mL
(21 000 mU/L).
One year later, despite treatment with DA, regrowth of the
lesion’s cystic component and worsening of the neurological
symptoms led to a redo craniotomy for mass resection. The
aggressiveness of the lesion was then evident and proved by
immunohistochemistry of the removed adenoma tissue. At
10 years of follow-up, after two surgeries and under high doses
of cabergoline, the patient remains with hyperprolactinaemia,
hypogonadism and residual tumour on MRI. At this point, our
main concerns are the maintenance of prolactin secretion and
hypogonadism, the high doses of cabergoline needed and the
eventual requirement of other treatment options in the future.
We could not achieve the classic prolactinoma treatment goals,
but these goals are not realistic in giant prolactinomas. Some
authors consider that the priority in the management of these
tumours is the control of the mass effect.1 3 In our case, there
was an effective and progressive reduction in tumour size and
its secretion, leading to the recovering of neuronal changes.
The residual tumour can explain the maintenance of hormo-
nal hypersecretion.12 Albeit very slowly, the tumour continues
to decrease its secretion, resulting in consecutively lower prolac-
tin serum values. DA resistance can be defined as failure to nor-
malise prolactin on maximally tolerated doses of DAs and the
absence of tumour size reduction ≥50%.13 Moraes et al
contend that in giant prolactinomas the term ‘insufficient
response to DAs’ may be more appropriate because, as in our
case report, there is a response to DA drugs in these tumours,
but a normal prolactin level may not be achieved due to tumour
size and very high prolactin levels at diagnosis.3 This demon-
strates the need for long-term therapy in giant prolactinomas.1
The high doses of cabergoline used are a real concern. Our
patient has been treated for 7 years with a high dose of cabergo-
line (cabergoline cumulative dose: almost 1800 mg). However,
until now, no side effects, namely pathological changes in
Figure 3 Prolactin levels in 10 years of follow-up and corresponding medical treatment. * PRL (prolactin) levels represented in number of times
the upper limit of normal.
Figure 4 (A) MRI at 5 years of follow-up (coronal view). (B) MRI at 5 years of follow-up (sagittal view).
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annual echocardiograms, have been observed. Treatment with
cabergoline has been associated with unusual short-term side
effects related to tumour shrinkage, such as cerebrospinal fluid
leakage, chiasmal herniation and pituitary apoplexy. However,
the main concerns of cabergoline use are related to its cumula-
tive dose and long-term potential cardiac effects.4 14 15 This
drug has been associated with subclinical lesions, such as aortic
calcifications and tricuspid regurgitation and periodic echocar-
diographic monitoring is recommended in these patients.3 15–17
Mitral valve insufficiency has also been reported in Parkinson’s
disease patients treated with high doses of cabergoline.14 18
Therefore, use of the lowest effective dose should be recom-
mended in order to minimise the risk of side effects. In the
large study by Delgrange et al,19 there was no advantage in
increasing the dose above 3.5 mg/week, but very few studies
have tried to define a dose threshold above which further
response is unlikely to occur.4 7 Despite this, prolonged treat-
ment with high doses of cabergoline has been reported to be
safe in patients with giant prolactinomas.14 Reassuring data have
been provided by studies in patients with Parkinson’s disease
treated with high doses of carbergoline (up to 21 mg per
week).18
Another important concern in our patient is epilepsy, as it
affects his quality of life. Although different antiepileptic drugs
have been used, he still has, on average, more than three seizures
per year. This problem can result from sequelae of the cranioto-
mies and/or from the pituitary lesion’s mass effect before
treatment.
Other treatment options have been considered. The remain-
ing tumour is an infiltrative lesion that is adherent to the visual
pathways, skull base and its vessels. These anatomical character-
istics make surgery and radiotherapy (even γ knife radiation)
unattractive and possible side effects unacceptable. According to
Moraes et al,3 in a residual unresectable tumour without mass
effect and no biochemical control despite increasing cabergoline
dose, the most correct approach is hypogonadism treatment.
Immunohistochemistry of the tumour revealed a high prolif-
erative index of 7% (using the Ki-67 antibody) and p53 immu-
noreactivity of 42%. This is illustrative of the aggressiveness of
this tumour, which can explain its clinical course and highlights
the requirement for lifelong follow-up of the patient.20 Another
important point is the malignant potential of the tumour. At
present, it remains responsive to cabergoline and the MRI is
stable. However, if unresponsiveness to DAs develops or metas-
tases appear, other treatment options must be considered.
Temozolamide is a chemotherapy agent that has been used in
aggressive pituitary tumours, including giant prolactinomas,
with good results, and can be a helpful option.1 21
Therefore, in our opinion, the maintenance of 5 mg of caber-
goline per week and hypogonadism treatment with careful sur-
veillance seems to be the most appropriate management at this
time. New medical therapies are being studied and might
become important options in the future.
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Learning points
▸ The therapeutic goals of prolactinomas (normalisation of
hormone levels, re-establishment of eugonadism and
reduction of tumour size) are often not realistic in giant
prolactinomas.
▸ The therapeutic management of giant prolactinomas is a
challenge.
▸ The first-line therapy of giant prolactinomas is dopamine
agonist therapy, but other therapeutic approaches may be
necessary.
▸ Lifelong medical therapy in giant prolactinomas is usually
needed.
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